Synagis (Palivizumab)

Synagis (Palivizumab) is a medication used to help protect infants and young children, especially those at high risk, from severe respiratory infections caused by the respiratory syncytial virus (RSV). It is a monoclonal antibody administered through injections during RSV season. Synagis works by attaching to the virus, preventing it from entering cells and causing infection. It's not a vaccine but provides passive immunity, reducing the chances of serious illness in vulnerable children, such as preterm infants or those with certain lung or heart conditions. It is typically given monthly during RSV season to offers protection.